Tailoring a molecule’s properties to improve its developability, half-life, and physico-chemical properties, will greatly improve its chances of success in the clinic, and is a critical first step to determining a molecule's druggability. The 14th Annual Optimisation & Developability conference will present strategies to optimise drug properties, assess and predict stability, aggregation and immunogenicity risk, by using a toolbox of molecule modeling, deep learning, in silico approaches, as well as the latest AI and machine learning methods.